Multi-institutional clinical study for dogs with non-azotemic primary glomerular disease
To evaluate the effects of titrating up doses of enalapril on maximal reductions in urine protein excretion. The current recommended enalapril dose was established using 75% suppression of ACE activity as the desired pharmacodynamic end-point. However, recent studies in people suggest that higher doses may be required for maximal reduction in urine protein excretion and may dramatically improve patient survival.
Participants will be randomized into either a standard enalapril dose or an up-titrated enalapril dose group. Dogs in the standard dose group will have follow-up visits at 12, 24 and 36 weeks. Dogs in the up-titrated dose group will have the dose of enalapril gradually increased over 1-2 visits (weeks 3 and 6) until the maximal reduction in urine protein: creatinine ratio is noted, then follow-up visits at 12, 24 and 36 weeks.
All initial and follow-up visits will be performed at the NCSU Randall B. Terry, Jr. Companion Animal Veterinary Medical Center.
- A diagnosis of proteinuric renal disease that is unlikely to be secondary to a concurrent disease.
- A urine protein: creatinine ratio > 3.0 in the absence of cytologic evidence of lower urinary tract disease.
- Serum creatinine concentration >1.5 mg/dl
- Nephrotic syndrome
- Concurrent disease which may alter glomerular filtration rate or is associated with an expected survival of <12 months
- Study pays for $300 of initial visit of eligible dogs, which will include CBC, chemistry panel, urinalysis, urine protein:creatinine ratio, systolic blood pressure, abdominal ultrasound and glomerular filtration rate.
- All recheck exams and tests are covered fully by the study.
Tonya Harris: 919-513-6206, email@example.com
Page last updated September 04, 2013